Big Money Are Buying Biomerica Inc (BMRA), Sentiment at 1

May 16, 2018 - By Amber Marburger

Biomerica, Inc. (NASDAQ:BMRA) Corporate Logo

Biomerica Inc’s Sentiment

In Q4 2017 Biomerica Inc (BMRA) big money sentiment increased to 1, according to SEC.gov filings. That’s up 0.75, from 2017Q3’s 0.25. 4 investment managers increased and started new equity positions, while 4 trimmed and sold positions in Biomerica Inc so the sentiment is more positive. These funds own 109,831 shares, that’s up from 66,682 shares in 2017Q3. Funds holding Biomerica Inc in top 10 changed to 0 from 0 for the same number . 2 Investors Sold All; 2 Reduced Holdings; 0 increased stakes while 4 investment managers bought stakes.

Most Biomerica Inc Investors

Bank Of America Corp De owns 3,832 shares in Biomerica Inc as of Q4 2017. As of Q4 2017, 2,200 shares of Biomerica Inc are owned by Deutsche Bank Ag. In addition, Millennium Management Llc reported 11,167 shares in Biomerica Inc equivalent to 0% of its fund’s portfolio. Morgan Stanley revealed 1 shares position in Biomerica Inc. The Massachusetts-based fund Panagora Asset Management Inc holds 6,347 shares or 0% of their fund’s portfolio.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide.The firm is worth $30.80 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.Last it reported negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

The stock increased 1.42% or $0.05 during the last trading session, touching $3.56.Biomerica, Inc. has volume of 1,601 shares. Since May 16, 2017 BMRA has risen 113.88% and is uptrending. BMRA outperformed by 102.33% the S&P500.

Biomerica, Inc. (NASDAQ:BMRA)’s earnings report is awaited by WallStreet on August, 29, according to Faxor. The earnings per share diference is $0.02 or 50.00 % down from last years number. Previous year: $-0.04; Analysts forcast: $-0.06. After $-0.04 EPS report last quarter, Wall Street now forecasts 50.00 % negative EPS growth of Biomerica, Inc..

Millennium Mgmt Limited Liability holds 0% or 11,167 shs. Deutsche Bancorp Ag owns 0% invested in Biomerica, Inc. (NASDAQ:BMRA) for 2,200 shs. 79,642 are held by Vanguard Group. Panagora Asset holds 0% or 6,347 shs. Retail Bank Of America De reported 3,832 shs or 0% of all its holdings. Tower Research Limited Liability Company (Trc) stated it has 142 shs. Morgan Stanley invested 0% of its capital in Biomerica, Inc. (NASDAQ:BMRA). Wells Fargo & Mn owns 6,500 shs.

Biomerica, Inc. had 0 sales and 4 insider buys since January 23, 2018. This’s net activity of $65,333. On Wednesday, January 24 CANO FRANCIS bought $49,324 worth of Biomerica, Inc. (NASDAQ:BMRA) or 11,800 shs.

Another two news for Biomerica, Inc. (NASDAQ:BMRA) were briefly published by: Globenewswire.com on April 17, 2018 with title “Biomerica Announces Third Quarter Financial Results”. The other Globenewswire.com‘s article was titled “Biomerica adds Harry Leider, MD, MBA to Strategic Advisory Board” and published on April 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: